The addition of doxycycline to fluoroquinolones for bacterial prophylaxis in autologous stem cell transplantation for multiple myeloma

• Published in: Transplant infectious disease Vol. 26; no. 2; p. e14241
• Main Authors: Guare, Emma G., Hale, Cory M., Sivik, Jeffrey, Lehman, Erik, Inoue, Yoshika, Rakszawski, Kevin, Songdej, Natthapol, Nickolich, Myles, Zheng, Hong, Naik, Seema, Claxton, David, Rybka, Witold, Hohl, Raymond, Mineishi, Shin, Minagawa, Kentaro, Paules, Catharine I.
• Format: Journal Article
• Language: English
• Published: Denmark Wiley Subscription Services, Inc 01.04.2024
• Subjects: Anti-Bacterial Agents - therapeutic use; Antibiotic Prophylaxis; Antibiotic resistance; Antimicrobial resistance; Autografts; Bacteremia; Bacteremia - epidemiology; Bacteremia - microbiology; Bacteremia - prevention & control; Bacteria; Ceftriaxone; Disease prevention; Doxycycline; Doxycycline - therapeutic use; E coli; Fever; Fluoroquinolones; Fluoroquinolones - pharmacology; Fluoroquinolones - therapeutic use; Hematopoietic Stem Cell Transplantation - adverse effects; Humans; Multiple myeloma; Multiple Myeloma - therapy; Neutropenia; Prophylaxis; Regression analysis; Retrospective Studies; Stem cell transplantation; Stem cells; Transplantation, Autologous - adverse effects; Transplants & implants; autologous stem cell transplant; multiple myeloma; antimicrobial resistance; fluoroquinolone; doxycycline; bacteremia; bacterial prophylaxis

Bacterial prophylaxis with a fluoroquinolone (FQ) during autologous stem cell transplant (ASCT) is common, although not standardized among transplant centers. The addition of doxycycline (doxy) to FQ prophylaxis was previously linked to reduced neutropenic fever and bacteremia in multiple myeloma (M...